New hope for older AML patients: gentler treatment combo under the microscope
NCT ID NCT07014462
Summary
This study is testing whether adding a common anti-inflammatory drug, dexamethasone, to a standard low-intensity leukemia treatment is safe and tolerable. It is for adults newly diagnosed with Acute Myeloid Leukemia (AML) who cannot receive strong chemotherapy. The main goal is to check for side effects, while also looking at how well the treatment works and its impact on quality of life.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AML (ACUTE MYELOID LEUKEMIA) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University of Vermont Medical Center
Burlington, Vermont, 05401, United States
Conditions
Explore the condition pages connected to this study.